

REPORT OF THE FOURTEENTH
WHOPES
WORKING GROUP MEETING

WHO/HQ, GENEVA
11—15 APRIL 2011

Review of:

SPINOSAD® EC
LIFENET® LN
MAGNET™ LN
ROYAL SENTRY® LN
YAHE® LN



**World Health
Organization**

REPORT OF THE FOURTEENTH WHOPES WORKING GROUP MEETING

**WHO/HQ, GENEVA
11–15 APRIL 2011**

REVIEW OF:

**SPINOSAD[®] EC
LIFENET[®] LN
MAGNET[™] LN
ROYAL SENTRY[®] LN
YAHE[®] LN**



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

Report of the fourteenth WHOPES working group meeting: WHO/HQ, Geneva, 11-15 April 2011: review of spinosad □ EC, lifenet □ LN, magnetTM LN, royal sentry □ LN, yahe □ LN.

1.Malaria - prevention and control. 2.Mosquito control. 3.Pesticides. 4.Permethrin - pharmacology. 5.Nitriles - pharmacology. 6.Pyrethrins - pharmacology. 7.Macrolides - pharmacology. 8.Bedding and linens. 9.Clinical trials. I.World Health Organization. II.WHO Pesticide Evaluation Scheme. Working Group. Meeting (14th: 2011: Geneva, Switzerland)

ISBN 978 92 4 150216 0

(NLM classification: QX 600)

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for non-commercial distribution – should be addressed to WHO Press at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied.

The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The recommendations of the World Health Organization Pesticide Evaluation Scheme (WHOPES) are intended to facilitate the registration and use of the evaluated products by the Member States of the World Health Organization. A recommendation or interim recommendation concerning a specific product means that the World Health Organization has evaluated that product in laboratory and field trials and that the product was found to meet the criteria and requirements of the World Health Organization.

For long-lasting insecticidal mosquito nets (LNs), the World Health Organization may – pending the completion of long-term studies that may be required to fully evaluate such LNs and subject to certain conditions being met – issue an interim recommendation for the use of such LNs for prevention and control of malaria.

A recommendation or interim recommendation does not imply any approval by the World Health Organization of the product in question (which is the sole prerogative of national authorities).

Such a recommendation or interim recommendation does not, furthermore, constitute any assurance by the World Health Organization that the manufacture, distribution, sale and/or use of the product in question is in accordance with the national laws and regulations of any country, including, but not limited to, patent law.

The recommendations and interim recommendations included in this publication may not be used by manufacturers, suppliers or any other parties for commercial or promotional purposes. Manufacturers are, however, permitted to discreetly mention the outcome of the WHOPES evaluation in non-commercial material which is addressed to national public health professionals and/or pesticide registration authorities only (that is, through a statement that the product in question was found to have been manufactured in accordance with the applicable specification recommended by the World Health Organization).

A recommendation or interim recommendation does not constitute an endorsement, or warranty of the fitness, by the World Health Organization of any product for a particular purpose, nor does such a recommendation or interim recommendation constitute the expression of any opinion whatsoever about the product's suitability for the control of any given pest, or for use in any particular geographical area.

CONTENTS

	Page
1. INTRODUCTION	1
2. REVIEW OF SPINOSAD® EC	4
2.1 Efficacy – WHOPES supervised trials	5
2.2 Conclusions and recommendations	11
3. REVIEW OF LIFENET® LN	18
3.1 Safety assessment	18
3.2 Efficacy – background and supporting documents	19
3.3 Efficacy – WHOPES supervised trials	20
3.3.1 Laboratory studies	20
3.3.2 Experimental hut studies	22
3.4 Conclusions and recommendations	29
4. REVIEW OF CANDIDATE LNS FOR EXTENSION OF WHO SPECIFICATIONS	39
4.1 Materials and methods	40
4.2 Results	42
4.2.1 MAGNet™ LN	42
4.2.2 Royal Sentry® LN	44
4.2.3 Yahe® LN	46
4.3 Conclusions and recommendations	48
5. GENERAL RECOMMENDATIONS	65
ANNEX I LIST OF PARTICIPANTS	76
ANNEX II REFERENCES	77

1. INTRODUCTION

The fourteenth meeting of the WHOPES Working Group, an advisory group to the WHO Pesticide Evaluation Scheme (WHOPES), was convened at WHO headquarters in Geneva, Switzerland, from 11 to 15 April 2011. The objective of the meeting was to review Spinosad EC (Clarke Mosquito Control, USA) for mosquito larviciding; and LifeNet[®] (Bayer CropScience, France) for malaria prevention and control. The meeting also assessed the regeneration, wash resistance and efficacy of MAGNet[™] LN (VKA Polymers, India), Royal Sentry[®] LN (Disease Control Technologies, USA) and Yahe[®] LN (Fujian Yamei Industry, China) as part of the requirements for extending WHO specifications to these products.

The meeting also addressed issues and challenges related to procedures, criteria and requirements for testing and evaluation of public health pesticides, and made appropriate recommendations.

The meeting was attended by 11 scientists (see Annex I: List of participants). Professor Dr Marc Coosemans was appointed as Chairman and Dr John Gimnig as Rapporteur. The meeting was convened in plenary and group sessions, in which the reports of the WHOPES supervised trials and relevant published literature and unpublished reports were reviewed and discussed (see Annex II: References). Recommendations on the use of the above-mentioned products were made.

Declaration of interests

All invited experts were requested to complete a WHO Declaration of Interests form prior to the meeting. The following interests were declared:

Dr. Rajendra Bhatt's institute has received prescribed standard fees from six manufacturers of pesticide products (BASF India, Bayer CropScience India, Clarke Mosquito Control USA, Sumitomo Chemicals India, Syngenta Crop Protection India and Vestergaard Frandsen India) in order to meet the costs of product evaluation.

Dr Marc Coosemans' research unit has received long-lasting insecticidal mosquito nets (LNs) free of charge from Sumitomo Chemicals Japan for use in a study on long-lasting insecticidal hammocks in Cambodia and Viet Nam. In addition, his research unit received a grant from UBS Bank for the same research project.

Dr Vincent Corbel's institute has received grants from DART (a joint venture between Vestergaard Frandsen, the Acumen Fund and Richard Allan), for testing and evaluation of its durable wall lining products, and from Vestergaard Frandsen for testing and evaluation of its LNs. In addition, his travel to a malaria meeting in Nairobi in 2009 was paid for by Vestergaard Frandsen.

Dr John Gimnig's research unit has received larvicide for testing from Clarke Mosquito Control, USA, to the value of US\$ 800.

Dr Olivier Pigeon's institute has received prescribed standard fees from VKA Polymers and Bayer CropScience in order to meet the costs of testing LNs manufactured by the companies.

Dr Fabrice Chandre's institute has received prescribed standard fees from Sumitomo Chemicals Japan, Bayer CropScience Germany and SPCI France in order to meet the costs of evaluating their respective LNs. In addition, his travel to a malaria meeting in Nairobi in 2009 was paid for by Bayer Environmental Science France.

Dr Mark Rowland's research unit has received grants from Bayer Environmental Sciences and Vestergaard Frandsen for testing and evaluation of their LNs, as well as from Innovative Vector Control Consortium (IVCC) for laboratory and field testing of different insecticide products.

The interests declared by the experts were assessed by the WHO Secretariat. With the exception of Dr Chandre's declared personal interest and Dr Mark Rowland's declared interest on the part of his research unit, the declared interests were not found to be directly related to the topics under discussion at the meeting; the discussion was aimed at evaluating the pesticide products manufactured by Bayer CropScience, France; Clarke Mosquito

Control, USA, Disease Control Technologies, USA; Fujian Yamei Industry, China; and VKA Polymers, India. It was, therefore, decided that all of the above-mentioned experts (with the exception of Dr Chandre and Dr Rowland) could participate in all evaluations, subject to the public disclosure of their interests.

In view of his declared personal interest, Dr Chandre did not participate in the evaluation of Bayer's LifeNet LN.

In view of the declared interest on the part of his research unit, Dr Rowland did not participate in the evaluation of Bayer CropScience's LifeNet LN.

已结束，完整报告链接和二维码如下

www.yunbaogao.cn/report/index/report?reportId=5_28639